The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes

Abstract

References

C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus

C-peptide secretion during the remission phase of juvenile diabetes

Beta cell dysfunction in maturity-onset diabetes: reversible loss of glucose-induced insulin secretion with retention of response to arginine

Abnormalities of endogenous glucagon and insulin in unstable diabetes

Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus

Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine

Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons

Reproducibility of the glucagon test

The effect of glucose, tolbutamide, and arginine on C-peptide release during remission in type I diabetes mellitus

Differential sensitivity to beta-cell secretagogues in "early," type I diabetes mellitus

C-peptide response to arginine stimulation in diabetic children

Plasma C-peptide response to arginine in insulin-dependent diabetic subjects

Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus

Successful islet transplantation: continued insulin reserve provides long-term glycemic control

Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials

Citations

Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes

CXCR1/2 inhibition enhances pancreatic islet survival after transplantation

Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes

Response to comment on: Besser et al. Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013;36:195-201

A SNP in G6PC2 predicts insulin secretion in type 1 diabetes

Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes

The classification of diabetes mellitus: a conceptual framework

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

Transplant estimated function: a simple index to evaluate beta-cell secretion after islet transplantation

Beta-score: an assessment of beta-cell function after islet transplantation

Capturing residual beta cell function in type 1 diabetes

Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)

Impact of acute-phase insulin secretion on glycemic variability in insulin-treated patients with type 2 diabetes

Natural history of beta-cell function in type 1 diabetes

Related Concepts

Related Feeds

American Diabetes Association Journals

Autoimmune Diabetes & Tolerance

Related Papers

Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents

Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children

Effects of insulin in relatives of patients with type 1 diabetes mellitus

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

Diabetes, obesity, and the brain